Regarding androgens, AR is a potential marker for predicting pathological response in HER2 BC patients treated with trastuzumab plus pertuzumab neoadjuvant therapy [147], and pre-clinical studies with the AR antagonist enzalutamide proved that this agent can avoid trastuzumab resistance [148]. Here, ERBB2 is linked to breast cancer.